



Safety first with Liver Safety+

The only platform that allows you to predict liver safety during discovery

With Liver Safety+, you can design and optimize your drug compounds for efficacy using the powerful and proven ADMET Predictor® platform—and then prioritize your most promising candidates by likelihood of liver safety concern.

It's no longer necessary to synthesize and test new candidates in the laboratory to get the data needed for drug-induced liver injury (DILI) predictions. With Liver Safety+, you can generate data from industry-leading machine learning models during discovery that allows you to parameterize and utilize the robust DILIsym® platform for reliable DILI prioritization.



Liver Safety+ provides...

- ✓ Powerful discovery and optimization with ADMET Predictor
- ✓ Leading high-throughput PK (HTPK) models
- ✓ Structure-based assessment of liver safety mechanism activity
- ✓ Rank ordering of relative DILI risk across a group of compounds with proven DILIsym technology
- ✓ Unlimited access to on demand workflow training

Identify DILI risk during discovery, and steer your development time and resources to the compounds likeliest to achieve success.

Rev. 10/30/2024